Pfizer points to newer meds—including Ibrance—as post-Upjohn cash engines

On the heels of news it would spin off its generics wing, Pfizer is looking at a much different future without its $2.8 billion cash cow. But CEO Albert Bourla has a message for investors concerned about that uncertainty: The future is bright—just look at our sales.